Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Pasithea Therapeutics Corp (KTTA)

Pasithea Therapeutics Corp (KTTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 GlobeNewswire - Tue Jul 21, 6:00AM CDT

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit GlobeNewswire - Wed Jul 8, 6:02AM CDT

MIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion GlobeNewswire - Tue Jun 30, 6:00AM CDT

--  Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial GlobeNewswire - Tue Jun 16, 6:00AM CDT

-- Remains on track to release interim NF1 data update in Q4 2026 -- -- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference GlobeNewswire - Mon Jun 15, 6:02AM CDT

-- Company will engage with NF1 community following recent FDA Fast Track and Rare Pediatric Disease Designations for lead NF1 treatment candidate PAS-004 – – Participants interested in meeting...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire - Tue Jun 2, 6:02AM CDT

MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer GlobeNewswire - Mon May 4, 6:01AM CDT

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) GlobeNewswire - Mon Apr 20, 6:01AM CDT

MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity GlobeNewswire - Wed Apr 1, 6:01AM CDT

MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference GlobeNewswire - Tue Feb 17, 6:01AM CST

– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET – – Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics...

KTTA : 0.4550 (-5.25%)
KTTAW : 0.0096 (+35.21%)

Barchart Exclusives

No Matter Who Wins the Smartphone and AI Chip Races, ARM Stock Still Benefits Barchart - Sat Jul 25, 2:30PM CDT
Arm now leads x86 in AI servers and collects royalties from every chipmaker, including the ones it competes with. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.